Bruce Sachais, MD, PhD

Senior Vice President, Enterprise Chief Medical Officer and Head of Translational Research and Development Laboratory

Bruce Sachais, MD, PhD, is the Chief Medical Officer for New York Blood Center Enterprises. He also serves as the Medical Director for the Blood Bank of Delmarva and is Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College. 

After receiving his BA in Chemistry from Lehigh University, he earned his MD/PhD (Neuroscience) from Washington University in St. Louis. He completed his clinical pathology residency and his fellowship in transfusion and apheresis medicine at the Hospital of the University of Pennsylvania, where he remained as faculty, attaining the rank of Associate Professor before moving to New York.

His basic research focuses on platelets and the platelet protein Platelet Factor 4. His lab is currently focused on the development of novel therapeutics for Heparin Induced Thrombocytopenia, as well as improving the safety of blood products. His clinical research has encompassed a variety of topics in the fields of Transfusion and Apheresis Medicine. As a member of the Transfusion Medicine and Hemostasis (TMH) Clinical trials network, he has participated in a variety of studies including PLADO, HIT-RADIO and RE-START. He is currently the Co-Principal Investigator of the NY HUB for REDS-IV-P; an NHLBI funded research consortium focused on improved blood transfusion practices.

He has co-authored over 75 peer review publications and is a past member of the AABB Clinical Transfusion Medicine Committee.  He is a past member of the ASFA Board of Directors (2009-2018) and served as ASFA President (2016-17). He is currently the Vice President for the Americas for ISFA, the International Society for Apheresis.